Skip Ribbon Commands
Skip to main content
SharePoint
A- A A+
Home > For Patients & Visitors > Find a Doctor

For Patients & Visitors

Find a Doctor

Find a Doctor

Dr Anand Jeyasekharan

Photo of Dr Anand Jeyasekharan
Tel:
+65 6773 7888
URL:
https://www.ncis.com.sg
Designations:
  • Consultant, Department of Haematology-Oncology, National University Cancer Institute, Singapore
  • Assistant Professor, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore
Qualifications:
MBBS (CMC Vellore, India), MRCP (UK), PhD (Cantab), FAMS (Medical Oncology)
Specialties:
Haematology, Medical Oncology
Special Interests:
Lymphomas, Sarcomas, Personalised Medicine and Immuno-Oncology 

Make an Appointment

Biosketch

Dr Jeyasekharan obtained his undergraduate medical degree from Christian Medical College Vellore, India in 2003. He then received a Gates Cambridge Scholarship towards a PhD in Oncology (2008) at the University of Cambridge UK (Gonville and Caius College). Following a junior research fellowship in Cambridge (Wolfson), he joined the National University Hospital Singapore in 2010 to complete his training in Internal Medicine and Medical Oncology.
 
Dr Jeyasekharan has a special interest in the treatment of lymphomas/sarcomas, as well as personalized therapy for rare and advanced cancers. He holds a joint appointment at the Cancer Science Institute, where he runs a translational cancer research laboratory. His laboratory focuses on understanding how the tumour microenvironment impacts the efficacy of chemotherapy. Dr Jeyasekharan holds multiple internal and nationally funded grants to support his research, and is a platform lead for a national translational research program in cancer through the Singapore Translational Cancer Consortium (STCC).

Awards

  • 2021: Clinician Scientist Award Investigator, National Medical Research Council Awards
  • 2017: Transition Award, National Medical Research Council Awards

Journals & Publications

  1. Hoppe, M. M., P. Jaynes, F. Shuangyi, Y. Peng, S. Sridhar, P. M. Hoang, C. X. Liu, S. De Mel, L. Poon, E. H. L. Chan, J. Lee, C. K. Ong, T. Tang, S. T. Lim, C. Nagarajan, N. F. Grigoropoulos, S.-Y. Tan, S. S.-S. Hue, S.-T. Chang, S.-S. Chuang, S. Li, J. D. Khoury, H. Choi, C. H. III, A. Bottos, L. J. Gay, H. F. P. Runge, I. Moutsopoulos, I. Mohorianu, D. J. Hodson, P. Farinha, A. Mottok, D. W. Scott, J. J. Pitt, J. Chen, G. Kumar, K. Kannan, W. J. Chng, Y. L. Chee, S.-B. Ng, C. Tripodo and A. D. Jeyasekharan (2023). "Patterns of Oncogene Coexpression at Single-Cell Resolution Influence Survival in Lymphoma." Cancer Discovery: OF1-OF20. doi:10.1158/2159-8290.Cd-22-0998.
  2. Goh, J., S. De Mel, M. M. Hoppe, M. B. Mohd Abdul Rashid, X. Y. Zhang, P. Jaynes, E. Ka Yan Ng, N. A. D. B. Rahmat, Jayalakshmi, C. X. Liu, L. Poon, E. Chan, J. Lee, Y. L. Chee, L. P. Koh, L. K. Tan, T. G. Soh, Y. C. Yuen, H.-Y. Loi, S.-B. Ng, X. Goh, D. Eu, S. Loh, S. Ng, D. Tan, D. M. Z. Cheah, W. L. Pang, D. Huang, S. Y. Ong, C. Nagarajan, J. Y. Chan, J. C. H. Ha, L. P. Khoo, N. Somasundaram, T. Tang, C. K. Ong, W.-J. Chng, S. T. Lim, E. K. Chow and A. D. Jeyasekharan (2022). "An ex vivo platform to guide drug combination treatment in relapsed/refractory lymphoma." Science Translational Medicine 14(667): eabn7824. doi:doi:10.1126/scitranslmed.abn7824.
  3. Ho, J. S. Y., B. W.-Y. Mok, L. Campisi, T. Jordan, S. Yildiz, S. Parameswaran, J. A. Wayman, N. N. Gaudreault, D. A. Meekins, S. V. Indran, I. Morozov, J. D. Trujillo, Y. S. Fstkchyan, R. Rathnasinghe, Z. Zhu, S. Zheng, N. Zhao, K. White, H. Ray-Jones, V. Malysheva, M. J. Thiecke, S.-Y. Lau, H. Liu, A. J. Zhang, A. C.-Y. Lee, W.-C. Liu, S. Jangra, A. Escalera, T. Aydillo, B. S. Melo, E. Guccione, R. Sebra, E. Shum, J. Bakker, D. A. Kaufman, A. L. Moreira, M. Carossino, U. B. R. Balasuriya, M. Byun, R. A. Albrecht, M. Schotsaert, A. Garcia-Sastre, S. K. Chanda, E. R. Miraldi, A. D. Jeyasekharan, B. R. TenOever, M. Spivakov, M. T. Weirauch, S. Heinz, H. Chen, C. Benner, J. A. Richt and I. Marazzi (2021). "TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation." Cell 184(10): 2618-2632.e2617.
  4. Hoppe, M. M., P. Jaynes, J. D. Wardyn, S. S. Upadhyayula, T. Z. Tan, S. Lie, D. G. Z. Lim, B. N. K. Pang, S. Lim, J. P. S. Yeong, A. Karnezis, D. S. Chiu, S. Leung, D. G. Huntsman, A. S. Sedukhina, K. Sato, M. D. Topp, C. L. Scott, H. Choi, N. R. Patel, R. Brown, S. B. Kaye, J. J. Pitt, D. S. P. Tan and A. D. Jeyasekharan (2021). "Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer." EMBO Mol. Med. 13(5): e13366.
  5. Ngoi, N., J. Lim, S. Ow, W. Y. Jen, M. Lee, W. Teo, J. Ho, R. Sundar, M. L. Tung, Y. M. Lee, E. Ngo, S. W. Lim, J. Ong, F. Lim, G. Bonney, B. Vellayappan, F. Ho, J. Tey, N. Chan, S. de Mel, M. Poon, S. Y. Lee, L. P. Koh, T. C. Liu, L. K. Tan, A. S. C. Wong, A. L. A. Wong, S. E. Lim, A. Yeoh, J. E. Wong, D. Tan, B. C. Goh, W. J. Chng, R. Soo, C. E. Chee, Y. L. Chee, S. C. Lee, A. D. Jeyasekharan for National University Cancer Institute (NCIS) (2020). "A segregated-team model to maintain cancer care during the COVID-19 outbreak at an academic center in Singapore." Ann. Oncol. 31(7): 840-843.
  6. de Mel, S., M. B. M. Rashid, X. Y. Zhang, J. Goh, C. T. Lee, L. M. Poon, E. H. L. Chan, X. Liu, W. J. Chng, Y. L. Chee, J. Lee, Y. C. Yuen, J. Q. Lim, B. K. H. Chia, Y. Laurensia, D. Huang, W. L. Pang, D. M. Z. Cheah, E. K. Y. Wong, C. K. Ong, T. Tang, S. T. Lim, S. B. Ng, S. Y. Tan, H.-Y. Loi, L. K. Tan, E. K. Chow and A. D. Jeyasekharan (2020). "Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma." Blood Cancer J. 10(1): 9.
  7. Hoppe, M. M., R. Sundar, D. S. P. Tan and A. D. Jeyasekharan (2018). "Biomarkers for Homologous Recombination Deficiency in Cancer." J. Natl. Cancer Inst. 110(7): 704-713.
  8. Jeyasekharan, A. D., Y. Liu, H. Hattori, V. Pisupati, A. B. Jonsdottir, E. Rajendra, M. Lee, E. Sundaramoorthy, S. Schlachter, C. F. Kaminski, Y. Ofir-Rosenfeld, K. Sato, J. Savill, N. Ayoub and A. R. Venkitaraman (2013). "A cancer-associated BRCA2 mutation reveals masked nuclear export signals controlling localization." Nat. Struct. Mol. Biol. 20(10): 1191-1201.
  9. Jeyasekharan, A. D., N. Ayoub, R. Mahen, J. Ries, A. Esposito, E. Rajendra, H. Hattori, R. P. Kulkarni and A. R. Venkitaraman (2010). "DNA damage regulates the mobility of Brca2 within the nucleoplasm of living cells." Proc. Natl. Acad. Sci. U. S. A. 107(50): 21937-21942.
  10. Ayoub, N., A. D. Jeyasekharan, J. A. Bernal and A. R. Venkitaraman (2008). "HP1-β mobilization promotes chromatin changes that initiate the DNA damage response." Nature 453(7195): 682-686.

Professional Memberships

  • ​Royal College of Physicians, London
  • Academy of Medicine, Singapore













National University Health System
  • National University Hospital
  • Ng Teng Fong General Hospital
  • Alexandra Hospital
  • Jurong Community Hospital
  • National University Polyclinics
  • Jurong Medical Centre
  • National University Cancer Institute, Singapore
  • National University Heart Centre, Singapore
  • National University Centre for Oral Health, Singapore (NUCOHS)
  • NUHS Diagnostics
  • NUHS Pharmacy
  • Blank logo
  • NUS - Yong Loo Lin, School of Medicine
  • NUS - Faculty of Dentistry
  • NUS - Saw Swee Hock, School of Public Health